RegeneRx President and CEO to Present at Maxim Group Growth Conference
16 Novembro 2010 - 5:30PM
Business Wire
RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (“the
Company” or “RegeneRx”) announced today that the Company will be
presenting at the Fourth Annual Maxim Group Growth Conference being
held at the Grand Hyatt New York in New York City on November 18,
2010. J.J. Finkelstein, RegeneRx’s president and chief executive
officer, will deliver the Company’s corporate presentation on
Thursday, November 18th, at 1:00 p.m. (Eastern Time).
To listen and view the presentation investors may either visit
RegeneRx’s homepage at www.regenerx.com or click on the following
link: http://www.wsw.com/webcast/maxim3/rgn/. An archived copy of
the presentation will also be available on RegeneRx’s website.
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the development of a novel therapeutic
peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection,
repair and regeneration. RegeneRx currently has three products
in clinical development.
RGN-352 is an injectable formulation to treat cardiovascular and
central nervous system diseases, as well as other medical
indications. RegeneRx is initially targeting RGN-352 for the
treatment of patients who have suffered an acute myocardial
infarction, or heart attack. Recent pre-clinical efficacy data
suggests that RGN-352 may also benefit patients with multiple
sclerosis, stroke and traumatic brain injury. RegeneRx has
successfully completed a Phase 1 clinical trial with RGN-352 in
which the drug candidate was found to be safe and well-tolerated.
The company has initiated a Phase 2 clinical trial and expects to
enroll the first patient by early 2011 at approximately 25 clinical
sites in the U.S., Israel, and Russia. RegeneRx is also supporting
a Phase 1/2 physician-sponsored clinical trial in patients with
multiple sclerosis that is expected to begin in 2011. RegeneRx
recently received a $3 million, three-year development grant from
the NIH to support the company’s acute myocardial infarction
program.
RGN-259 is a sterile, preservative-free topical eye drop for
ophthalmic indications. Based on recent human clinical data,
RegeneRx is currently supporting a physician-sponsored Phase 2 dry
eye study with RGN-259. Previously, seven patients with non-healing
corneal ulcers were treated with RGN-259 under compassionate use
INDs. Five had complete healing and two had substantial healing of
their wounds. Three additional patients with corneal defects,
called punctate keratitis, had no evidence of healing although they
did report reduction in eye inflammation and increased comfort.
RGN-137, a topical gel formulation, is currently being evaluated
by RegeneRx in a Phase 2 clinical trial for the treatment of the
orphan skin disease epidermolysis bullosa. Other potential uses for
RGN-137 include the treatment of chronic dermal wounds and
reduction of scar tissue. RegeneRx previously received $675,000 in
grants from the U.S. FDA to support this clinical trial.
In addition to the pharmaceutical product candidates described
above, RegeneRx is pursuing the commercial development of peptide
fragments of Tβ4 for potential cosmeceutical use. RegeneRx holds
numerous patents and patent applications worldwide related to its
products and holds an exclusive worldwide license from the National
Institutes of Health, as well as other licenses related to Tβ4. The
Company recently received $733,438 in funding under the Patient
Protection and Affordable Care Act to support each of its product
candidates.
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024